Recent studies have shown that it is far more tolerable than the older drug efavirenz, which patients have reported causes depression and hallucinations in the first few months and could lead to people not staying on treatment.

An antiretroviral drug dolutegravir, commonly known as DTG, is a drug that is more effective, easier to take and has fewer side effects than alternative drugs that are currently used. DTG also has a high genetic barrier to developing drug resistance, which is important given the rising trend of resistance to efavirenz and nevirapine-based regimens,” states the WHO.

Read More of DTG here:
https://omosomiblogsite.com/who-certifies-new-hiv-treatment-drug-safe/